Eton Pharmaceuticals (ETON)
(Delayed Data from NSDQ)
$3.51 USD
+0.01 (0.29%)
Updated Jul 22, 2024 04:00 PM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
ETON 3.51 +0.01(0.29%)
Will ETON be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for ETON based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ETON
Eton Pharmaceuticals, Inc. (ETON) Reports Q4 Loss, Lags Revenue Estimates
Cardiff Oncology (CRDF) Reports Q4 Loss, Tops Revenue Estimates
ETON: What are Zacks experts saying now?
Zacks Private Portfolio Services
Iovance Biotherapeutics (IOVA) Reports Q4 Loss, Misses Revenue Estimates
Eton Pharma (ETON) to Report Q4 Earnings: What's in the Cards?
Moderna (MRNA) Q4 Earnings and Revenues Beat Estimates
Other News for ETON
SWK Holdings Highlights Recent Achievements and Provides Portfolio Update
Eton Pharmaceuticals Announces FDA Acceptance of New Drug Application for ET-400 (Hydrocortisone Oral Solution)
Eton Pharmaceuticals, Inc. Q1 2024 Earnings Call Transcript
Wall Street Analysts Are Bullish on Top Healthcare Picks
Eton Pharmaceuticals Reports First Quarter 2024 Financial Results